We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cell therapy promotes axon remyelination in a mouse model
News

Cell therapy promotes axon remyelination in a mouse model

Cell therapy promotes axon remyelination in a mouse model
News

Cell therapy promotes axon remyelination in a mouse model

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cell therapy promotes axon remyelination in a mouse model "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons. This demyelination can be caused by an autoimmune response or impaired myelin production by oligodendrocytes.


See Also: Researchers present new view of myelin


A new report in JCI Insight from Arjun Saha and colleagues at Duke University demonstrates that a cell therapy product called DUOC-01 can accelerate remyelination of axons in mice treated with a demyelinating chemical agent.


DUOC-01 cells, which are derived from banked umbilical cord blood, were transplanted into mice following toxic demyelination. DUOC-01 treatment resulted in faster remyelination and promoted the differentiation of oligodendrocyte progenitor cells.


Learn More: Myelin-maker: How an FDA-approved drug boosts myelin synthesis


These results suggest that a cord blood-derived cell product can promote neuronal repair and remyelination. Future clinical studies will be needed to determine if DUOC-01 cell therapy benefits patients with demyelinating diseases.


Note: Material may have been edited for length and content. For further information, please contact the cited source.


JCI Journals


Publication

Saha A et al. A cord blood monocyte–derived cell therapy product accelerates brain remyelination.   JCI Insight, Published Online August 18 2016. doi: 10.1172/jci.insight.86667


Advertisement